Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.

This study found that nanostructured lipid carriers enabled effective follicular delivery and accumulation of anti-hair loss drugs like dutasteride in mice, suggesting potential for reduced dosage frequency.

This study found that applying a dutasteride-loaded liposome formulation to damp rat skin nearly doubled the drug's follicular accumulation compared to dry skin, suggesting scalp hydration status may significantly impact the drug's topical delivery, especially in follicle-rich areas.

This review reports that 5-alpha reductase inhibitors, used to treat androgenic alopecia, may adversely affect sperm count, sexual function, and hormones in a subset of patients.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This study found that scalp microinfusion with dutasteride using microneedling and tattoo devices appears safe and shows promise as a treatment for male androgenetic alopecia, resulting in stabilization or improvement in 96.7% of patients, although further controlled studies are needed.

In this series, patients experienced alopecia with limited regrowth following mesotherapy, indicating possible lasting aesthetic consequences and suggesting the need for careful technique and close follow-up, as the condition might be underrecognized.

Both finasteride and dutasteride can cause sexual side effects, but they may differ in frequency and severity.

Finasteride and dutasteride may increase the risk of depression and suicidality, so patients should be monitored closely.

In this randomized study, intradermal injections of dutasteride effectively improved androgenetic alopecia in 15 male patients, showing significant clinical improvement within one month and being well-tolerated without notable side effects, though the improvement was negatively correlated with longer disease duration.

The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.

This study found that a novel topical dutasteride lotion, FOL100, demonstrated excellent safety, tolerability, and usability with promising signs of clinical benefit for mild-to-moderate male pattern baldness.

In this study, both finasteride and dutasteride were effective for androgenetic alopecia, but dutasteride significantly improved hair density more than finasteride and had a comparable safety profile among men treated at an Indian center.

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.

This systematic review found that intralesional dutasteride treatments for androgenic alopecia in adults improved hair density and thickness with minimal adverse effects, although study methodologies varied and lacked large-scale trials.

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

Finasteride and dutasteride may cause depression and suicidal thoughts.

This study developed dutasteride-loaded microneedle systems using a specific polymer to enhance transdermal delivery, demonstrating efficient drug release and increased accumulation in hair follicles, thus supporting their potential for treating androgenic alopecia.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

In this study, twice-weekly and thrice-weekly dutasteride improved hair growth and were well-tolerated, although thrice-weekly dosing did not significantly outperform finasteride 1 mg daily for increasing hair count.

Finasteride and dutasteride can improve hair loss in women, but more research is needed.

This pilot study found that using skin patting with iontophoresis to deliver dutasteride gel significantly improved hair density, shaft diameter, and pull test scores in men and postmenopausal women with treatment-resistant androgenetic alopecia, with participants reporting high satisfaction and no adverse events.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

This study found that ethosomes containing 30% ethanol slightly improved the targeting of dutasteride to hair follicles in vitro, with a higher targeting factor compared to dried ethosomes and controls after 24 hours on porcine skin.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

In this report, four cases of noncicatricial alopecia developed following a single session of dutasteride mesotherapy in patients with androgenetic alopecia, highlighting potential adverse effects and the need for careful monitoring of the drug's composition.

Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.